Electrolyte Additive Products VC and FEC See Both Volume and Price Increases; Fuxiang Pharmaceutical Expects Q1 Net Profit Growth Exceeding 22 Times

LightningPacketLoss · 2026-03-25T00:02:36+00:00

Fuxiang Pharmaceuticals expects its net profit attributable to the parent company in the first quarter of 2026 to be between 52 million and 75 million yuan, representing a year-over-year increase of 2222.67% to 3250.01%. The growth in performance is driven by the favorable development of the new energy industry and the increasing demand for lithium battery materials, especially with the outstanding performance of the electrolyte additive business. Meanwhile, in 2025, the company's revenue reached 1.185 billion yuan, and its net loss attributable to the parent company was reduced to 53.0677 million yuan.

LightningPacketLoss

2026-03-25 00:02:36

Abstract generation in progress

On March 23, Fuxiang Pharmaceutical (300497.SZ) announced its Q1 2026 earnings forecast, expecting net profit attributable to shareholders of 52 million to 75 million yuan, a year-on-year increase of 2222.67% to 3250.01%.

Regarding the reasons for the performance change, Fuxiang Pharmaceutical stated that during the reporting period, benefiting from the continuous improvement in the new energy industry, steady growth in demand in the power battery market, and rapid explosion of demand in the energy storage battery market, upstream lithium battery materials demand continued to rise. The company’s lithium battery electrolyte additive business performed well, with core products such as VC and FEC experiencing both price and volume increases, thereby driving a significant year-on-year growth in the company’s performance.

Public information shows that Fuxiang Pharmaceutical mainly engages in the research, production, and sales of raw materials and intermediates for anti-infection drugs. Based on technological homology, the company has expanded into applications of chemical synthesis and biosynthesis, vigorously developing its lithium battery electrolyte additive business and expanding into synthetic biology microbial protein business.

According to the company’s performance brief for 2025 disclosed on the same day, the company achieved operating revenue of 1.185 billion yuan, a slight increase of 0.61% year-on-year; net profit attributable to shareholders was a loss of 53.07 million yuan, a reduction of 80.5% compared to the previous year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.